+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are studying long-term treatment options for patients with advanced solid tumors, including non-small cell lung cancer and colorectal cancer, who previously participated in studies involving adagrasib either alone or with other cancer therapies. This open-label continuation trial enrolls patients from ongoing parent studies to evaluate the ongoing effects and safety of these treatments. The trial is sponsored by Mirati Therapeutics Inc. and aims to provide insights into long-term treatment outcomes for these cancer types. Participants receive adagrasib and may also receive other cancer drugs such as pembrolizumab, cetuximab, pemetrexed, docetaxel, irinotecan, leucovorin, oxaliplatin, or fluorouracil. These drugs are given at specified doses on specified days within the trial. The study includes multiple experimental arms, reflecting different treatment combinations or sequences based on prior parent study participation. During the study, participants are monitored for adverse events, including serious side effects and events leading to treatment discontinuation or death, for up to 90 days after their last dose or if they stop the study early. Researchers track safety and tolerability through regular assessments. Participants remain under observation for the duration of their involvement, which extends until the study completion date in February 2028.

Age: 18Years +All GendersPhase 2
101 locations
R

Actively Recruiting

Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.

Age: 18Years +All GendersPhase 3
253 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combination therapy called BMS-986489 Atigotatug plus Nivolumab with Carboplatin and Etoposide compared to Atezolizumab with Carboplatin and Etoposide. This study focuses on participants with extensive-stage small cell lung cancer to understand which treatment works better as a first-line therapy. It is a Phase 3 clinical trial led by Bristol-Myers Squibb. Participants are randomly assigned to one of two groups one receiving the BMS-986489 combination with Carboplatin and Etoposide, and the other receiving Atezolizumab with Carboplatin and Etoposide. All medications are given at specific doses on designated days. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants undergo regular assessments including imaging scans to measure tumor size, and evaluations of overall survival over up to five years. Researchers also monitor symptoms, response duration, progression-free survival, and any adverse or serious side effects up to 135 days after treatment ends. The study includes detailed safety and efficacy tracking with multiple outcome measures to fully understand the impact of each treatment option.

Age: 18Years +All GendersPhase 3
183 locations
E

Actively Recruiting

Researchers are studying the effectiveness and safety of lorlatinib in patients with untreated ALK-positive non-small-cell lung carcinoma NSCLC. This research is conducted in a French real-world setting and sponsored by Pfizer. The study aims to assess how lorlatinib performs as a treatment option for this specific type of lung cancer. Participants will receive lorlatinib as a single-agent oral treatment at a dose of 100 mg daily. The study is designed as a single-group trial where patients continuously take lorlatinib. The treatment and observation period includes assessments up to 25 months, during which various outcomes such as progression-free survival, overall survival, response rates, and treatment duration will be evaluated. During the study, participants will be monitored regularly with imaging tests like CT scans and brain MRIs before starting treatment. Researchers will track treatment adherence, symptom changes, adverse events, and resistance mechanisms. Patient-reported outcomes and quality of life questionnaires will be collected at multiple time points up to 48 months. Safety and effectiveness measures will guide the ongoing evaluation, with follow-up visits scheduled throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
32 locations
E

Actively Recruiting

This research aims to evaluate the diagnostic cost-effectiveness of connected watch ECG versus the conventional 48-hour external Holter ECG in patients experiencing palpitations without electrocardiographic documentation during symptoms. Palpitations are a common reason for emergency and cardiological consultations, but their transient and infrequent nature makes diagnosis challenging. The study focuses on identifying the causal arrhythmia within six months following cardiological consultation. Participants will be equipped with a 48-hour Holter monitor and provided with a connected watch for six months. They will be instructed to record an ECG with the watch only when symptoms occur. The connected watch allows up to three per-critical ECG transmissions, with follow-up calls at two months to ensure proper use and monitor adherence. Both devices are used simultaneously to compare diagnostic yield and cost-effectiveness. During the study, participants will be monitored through the devices and event forms for symptom recording. Researchers will assess diagnostic profitability, types of diagnoses, rates of concomitant findings, and medical time per diagnosis over six months or until the watch is returned. The study includes follow-up for device usage, adverse events, and compliance, aiming to improve diagnostic strategies for palpitations.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a patient-centered Clinical Decision Support System CDSS called Lianeli to help primary care professionals identify patients eligible for recommended health screenings based on guidelines from the French National Authority for Health HAS. The study aims to improve shared decision-making between doctors and patients, address obstacles like lack of time and information, and reduce patient decision-making conflicts during preventive care consultations. The Lianeli platform is used first by patients through a health self-questionnaire and access to information sheets, then jointly by patients and their general practitioners during a prevention-focused consultation. This system matches individual patient data with national screening recommendations to suggest appropriate tests. The study uses a mixed approach including quantitative assessments of Lianelis use and qualitative interviews with patients and healthcare professionals to explore feasibility and satisfaction. Participants will complete questionnaires and take part in consultations using the Lianeli system, with follow-up assessments within 30 to 60 days after inclusion. Researchers will measure how fully Lianeli is used, patient and professional satisfaction, usability, and screening uptake. Interviews and focus groups will explore implementation factors. The total participation includes initial consultations, questionnaire completion, and follow-up evaluations to understand the impact of the CDSS in primary care prevention.

Age: 18Years - 74YearsAll GendersPhase Not Applicable
20 locations
A

Actively Recruiting

This research aims to evaluate the long-term safety of two different dose regimens of tozorakimab in adults with chronic obstructive pulmonary disease COPD who have a history of exacerbations. It is a Phase III, open-label, multicenter extension study including participants who have completed earlier related studies. The study is designed to assess how well participants tolerate the medication over an extended period. Participants receive subcutaneous injections of tozorakimab through pre-filled syringes, following one of two dose regimens based on their prior study participation. The study monitors these treatments chronically, lasting up to several years, to observe safety outcomes. This extension study allows continued dosing and long-term evaluation. During the study, participants will be regularly assessed for adverse events over 2 to 3 years. Researchers will monitor safety through ongoing clinical evaluations and collect data on any side effects experienced. Participants must consent and continue contraceptive use as agreed in previous studies. The study ensures close observation to understand the long-term impact of tozorakimab in managing COPD exacerbations.

Age: 18Years - 99YearsAll GendersPhase 3
13 locations
N

Actively Recruiting

Researchers are studying type I interferonopathies, which are rare genetic autoinflammatory disorders mainly affecting children but sometimes adults. These conditions often involve the central nervous system, joints, and occasionally blood abnormalities or immune deficiencies. They are caused by over-activation of the type I interferon pathway and tend to resist standard immunosuppressive treatments. The goal is to better understand the natural course of these diseases and their diverse clinical features. This observational study follows patients with genetically confirmed type I interferonopathies over a long period. It aims to characterize disease progression, identify immune factors linked to specific genotypes, find biomarkers for diagnosis and monitoring, and observe treatment responses based on patient phenotypes and genotypes. The study does not involve experimental treatments but collects data to improve future therapies. Participants will be monitored from 2025 through 2045. Data collection includes tracking disease evolution, immunological profiles, and treatment effectiveness. Researchers aim to clarify pathophysiological mechanisms and patient subgroups to guide personalized treatment options. Participation involves regular evaluations without experimental interventions, contributing to knowledge that supports better clinical trial design and patient care.

All AgesAll Genders
32 locations
R

Actively Recruiting

Researchers are conducting a French national observational study to evaluate patients with HER2-negative early breast cancer who are treated with olaparib. The study aims to understand how many patients complete the full adjuvant olaparib treatment in a real-world setting. This study observes patients receiving olaparib as part of their standard care without assigning treatments. Participants are those diagnosed with HER2-negative early breast cancer and starting adjuvant olaparib based on their physicians decision. The study does not provide or assign treatments but follows patients who are prescribed olaparib in routine clinical practice. There are no comparison groups or placebo treatments in this observational study. During the study, researchers will monitor patients for up to 18 months to measure the proportion who complete the full olaparib treatment course. They will also collect information on BRCA mutation characteristics, medical history, and the timing of treatment discontinuation. Participants will be observed through routine care without additional interventions, allowing researchers to assess real-world treatment adherence and outcomes.

Age: 18Years +All Genders
58 locations